Jiewen Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiewen Liu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Baoqi Yu
Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Laboratory for Clinical Medicine, Capital Medical University, Beijing, China
1 shared publication - Chenguang Niu
Department of Cardiology, The First Affiliated Hospital of Henan University, China
1 shared publication - Jie Chen
Peking University
1 shared publication - Siying Deng
Peking University
1 shared publication
Latest Publications
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 141-151
HDL Mimetic Peptides
Since therapeutic strategies designed to raise HDL failed to exert the expected effective cardiovascular disease (CVD) outcomes in clinical trials, how to improve HDL function rather than its plasma level has become a new focus of scientists’ attention. Numerous HDL mimetic peptides have been designed and investigated in various animal models in recent years. Although the underlying mechanisms are not fully understood, the peptides’ antiatherogenic effects, such as acceleration of RCT and improvement of natural HDL function without necessarily raising its level, showed a promising therapeutic role in the prevention of atherosclerosis and other diseases. This chapter reviews recent studies on the roles and potentials of HDL mimetic peptides in atherosclerosis-related CVD. Keywords Cardiovascular disease HDL Mimetic peptide Reverse cholesterol transport
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 141-151
HDL Mimetic Peptides
Since therapeutic strategies designed to raise HDL failed to exert the expected effective cardiovascular disease (CVD) outcomes in clinical trials, how to improve HDL function rather than its plasma level has become a new focus of scientists’ attention. Numerous HDL mimetic peptides have been designed and investigated in various animal models in recent years. Although the underlying mechanisms are not fully understood, the peptides’ antiatherogenic effects, such as acceleration of RCT and improvement of natural HDL function without necessarily raising its level, showed a promising therapeutic role in the prevention of atherosclerosis and other diseases. This chapter reviews recent studies on the roles and potentials of HDL mimetic peptides in atherosclerosis-related CVD. Keywords Cardiovascular disease HDL Mimetic peptide Reverse cholesterol transport
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 13-26
HDL and Cholesterol Ester Transfer Protein (CETP)
Cholesterol ester transfer protein (CETP) is important clinically and is one of the major targets in cardiovascular disease studies. With high conformational flexibility, its tunnel structure allows unforced movement of high-density lipoproteins (HDLs), VLDLs, and LDLs. Research in reverse cholesterol transports (RCT) reveals that the regulation of CETP activity can change the concentration of cholesteryl esters (CE) in HDLs, VLDLs, and LDLs. These molecular insights demonstrate the mechanisms of CETP activities and manifest the correlation between CETP and HDL. However, animal and cell experiments focused on CETP give controversial results. Inhibiting CETP is found to be beneficial to anti-atherosclerosis in terms of increasing plasma HDL-C, while it is also claimed that CETP weakens atherosclerosis formation by promoting RCT. Currently, the CETP-related drugs are still immature. Research on CETP inhibitors is targeted at improving efficacy and minimizing adverse reactions. As for CETP agonists, research has proved that they also can be used to resist atherosclerosis. Keywords Cholesterol ester transfer protein Anti-atherosclerosis Reverse cholesterol transport CETP inhibitor CETP agonists
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 13-26
HDL and Cholesterol Ester Transfer Protein (CETP)
Cholesterol ester transfer protein (CETP) is important clinically and is one of the major targets in cardiovascular disease studies. With high conformational flexibility, its tunnel structure allows unforced movement of high-density lipoproteins (HDLs), VLDLs, and LDLs. Research in reverse cholesterol transports (RCT) reveals that the regulation of CETP activity can change the concentration of cholesteryl esters (CE) in HDLs, VLDLs, and LDLs. These molecular insights demonstrate the mechanisms of CETP activities and manifest the correlation between CETP and HDL. However, animal and cell experiments focused on CETP give controversial results. Inhibiting CETP is found to be beneficial to anti-atherosclerosis in terms of increasing plasma HDL-C, while it is also claimed that CETP weakens atherosclerosis formation by promoting RCT. Currently, the CETP-related drugs are still immature. Research on CETP inhibitors is targeted at improving efficacy and minimizing adverse reactions. As for CETP agonists, research has proved that they also can be used to resist atherosclerosis. Keywords Cholesterol ester transfer protein Anti-atherosclerosis Reverse cholesterol transport CETP inhibitor CETP agonists